Clinical Trials

NDP-MIBG-IND: An Open Label, Expanded Access Protocol using I-MIBG Therapy for Patients with Refractory Neuroblastoma, Pheochromocytoma or Paraganglioma

What is the purpose of this study?

Currently there is no known effective treatment for patients with advanced stage neuroblastoma, pheochromocytoma, or paraganglioma who have relapsed or not responded to standard therapy. In previous studies that used 131I-MIBG as a potential anti-cancer therapy, a decrease in the size

of tumors was seen in some of the children and adults. This research study will continue to evaluate the side effects of 131I-MIBG when treating children and adults with neuroblastoma, pheochromocytoma, or paraganglioma. The 131I-MIBG compound is intended to work by selectively delivering the radioactive iodine to the tumor cells, which is then intended to result in their destruction.

The purpose of this research study is to:

  • Make 131I-MIBG therapy available to patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma
  • Further assess the side effects of 131I-MIBG therapy.

Who can participate?

Patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma who are 12 months and older.

Ages

  • From 1 To 99  years old

Conditions

  • Cancer - Neuroblastoma

What is involved?

CRITERIA

Inclusion Criteria

  • Diagnosis: Refractory/Relapsed neuroblastoma with original diagnosis based on tumor histopathology or elevated urine catecholamines with typical tumor cells in the bone marrow, OR pheochromocytoma or paraganglioma not amenable to curative surgery
  • Age ≥ 12 months and able to cooperate with radiation safety restrictions during therapy period with/without pharmacologic anxiolysis.
  • Disease status: Failure to respond to standard therapy (usually combination chemotherapy with/without radiation and surgery) or development of progressive disease at any time (any new lesion or an increase in size of > 25% of a pre-existing lesion). Disease evaluation must be completed within 8 weeks of study entry. If possible, the disease evaluation should take place subsequent to intervening therapy; if intervening therapy does occur, evaluations should be done as clinically indicated. If patient has received prior treatment with MIBG, they must have a response or stable disease after the most recent MIBG infusion. Patient may have PD after showing initial response to MIBG therapy (at [or around] the day 35-63 post-MIBG therapy evaluation).
  • Patients must have a hematopoietic stem cell product available for re-infusion after 131I-MIBG treatment at doses of ≥ 12 mCi/kg. If no stem cells are available, then the dose of 131I-MIBG should be < 12 mCi/kg.
    • The minimum quantity for purged or unpurged peripheral blood stem cells (PBSC) is 1.5 x 10e6 viable CD34+ cells/kg (recommended 2 x 10e6 viable CD34+ cells/kg).
    • The minimum dose for bone marrow is 1.0 x 10e8 mononuclear cells/kg (optimum > 2.0 x 10e8 mononuclear cells/kg).
  • Prior Therapy: Patients may enter this study with/without re-induction therapy for recurrent tumor. Patients must have fully recovered from the toxic effects of any prior therapy, meeting the following criteria: At least 2 weeks should have elapsed since any anti-tumor therapy and the patient must meet hematologic criteria below. Three-months should have elapsed in the case of completing radiation to any of the following fields: craniospinal, total abdominal, whole lung, total body irradiation (spot irradiation to skull-based metastases is NOT considered craniospinal radiation for the purposes of this study. Cytokine therapy must be discontinued a minimum of 24 hours prior to 131I-MIBG therapy.
  • Bilirubin ≤ 2x upper limit of normal; AST/ALT ≤ 10x upper limit of normal
  • Serum Creatinine ≤ 2x upper limit of normal OR 24-hr creatinine clearance OR GFR ≥ 60 ml/min/1.73m2(For example, a patient would meet this criteria if GFR < 60 ml/min/1.73m2 but serum creatinine ≤ 2x upper limit of normal.)
  • ANC ≥ 750/μL; Platelets ≥ 50,000/μL without transfusion if stem cells are not available (ANC ≥ 500 and any platelet count allowed if stem cells available). Patient must be off myeloid growth factors for at least 24 hours. If the patient has received prior treatment with MIBG, they may be thrombocytopenic, but requiring no more than 2 platelet transfusions per week to maintain counts above 20,000. Hemoglobin must be ≥ 10 gm/dL (transfusion allowed) regardless of stored stem cell availability.
  • Normal lung function as manifested by no dyspnea at rest or exercise intolerance, no oxygen requirement
  • No clinically significant cardiac dysfunction
  • Signed informed consent/assent: The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent/assent to become a study subject has been obtained, in accordance with institutional policies approved by the U.S. Department of Health and Human Services.

Exclusion Criteria

  • Patients with disease of any major organ system that would compromise their ability to withstand therapy. Significant organ impairment should be discussed with the Principal Investigator prior to patient entry.
  • No patients who are pregnant or lactating will be allowed. Patients of childbearing potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus. Abstinence is an effective method of birth control.
  • Patients who are on hemodialysis
  • Proteinuria, in the absence of urinary infection, within 4 weeks prior to the planned treatment date is a relative contraindication to receiving therapy for patients with pheochromocytoma/paraganglioma. Patients with pheochromocytoma/paraganglioma with any proteinuria must have a 24-hr urine protein determination. If proteinuria is confirmed as being above the institutional upper limit of normal, the patient is ineligible for MIBG therapy.
  • Patients with active infections that meet grade 3-4 according to the NCI CTCAE v4.0.
  • Patients with known MIBG-avid parenchymal brain metastases are not eligible. (Patients with leptomeningeal or skull-based metastases are eligible.)

Who should I contact for more information?

For more information contact:

Cincinnati Children’s Hospital Medical Center
Division of Hematology/Oncology
3333 Burnet Ave., Cincinnati, OH 45229-3039
Phone: 513-636-2799
cancer@cchmc.org

Where can I find additional information?